echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide

    AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text by Bu Yuan

    On February 24, the official website of China's National Medical Products Administration (NMPA) showed that AbbVie's JAK inhibitor upadatinib sustained-release tablets was officially approved.


    Previously, upatinib has been approved by the US FDA for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and atopic dermatitis (AD)-related indications


    JAK inhibitors are currently one of the most concerned medical research directions in the world.


    However, despite the many achievements, the road ahead for JAK inhibitors is not so easy


    Previously, because the FDA has issued risk warnings to JAK inhibitors and has repeatedly delayed the review of JAK inhibitor drugs, the safety challenges of JAK inhibitors have always attracted the attention of the industry


    01

    01

    JAK inhibitors

    JAK inhibitors

    The English name of JAK kinase is Janus Kinase, abbreviated as JAK.


    The JAK-STAT pathway is one of the few immunomodulatory pathways that have been proven so far, so JAK inhibitors can play a role in the field of autoimmune diseases


    Currently, JAK has discovered four family members:

    JAK1: mainly related to acute lymphoblastic leukemia, acute myeloid leukemia, solid organ malignancies; JAK2: mainly related to polycythemia vera, myelofibrosis, essential thrombocythemia and other diseases; JAK3: mainly related to acute megaloblastic Cell leukemia, T cell leukemia and lymphoma and other diseases; TYK2: mainly related to skin lymphoproliferative diseases and T cell leukemia


    The main JAK inhibitors that have been approved in the world are (based on the time of first listing):

    In 2011, the oral, ATP-competitive, and reversible JAK1/2 inhibitor ruxolitinib (Jakafi) studied by Incyte/Novartis was approved by the US FDA for the treatment of myelofibrosis (MF)


    .


    Among these approved JAK inhibitors, they are divided into—

    First-generation non-selective JAK inhibitors: ruxolitinib, tofacitinib, baricitinib, peficitinib, delgocitinib Second-generation selective JAK inhibitors: AbbVie’s upatinib (Rinvoq), Sanofi/Celgene’s fedratinib (Inrebic), Pfizer’s abrutinib (Cibinqo)

    In general, the first-generation non-selective JAK inhibitors all contain similar structures of adenine in ADP, so they generally have the problem of low selectivity.


    Second-generation JAK inhibitors can selectively inhibit JAK family members, so they can inhibit specific disease-related signaling pathways while maintaining the function of other cytokines unaffected, which is based on research and development


    02

    02

    Approved JAK inhibitors in my country and their research status

    Approved JAK inhibitors in my country and their research status

    With the approval of AbbVie Upatinib, 4 JAK inhibitors have been approved in China, and the remaining 3 are: Novartis' ruxolitinib, Eli Lilly's baricitinib, and Pfizer's tofacitinib Cloth, the indications mainly cover rheumatoid arthritis, myelofibrosis, atopic dermatitis


    In addition, the pharmaceutical companies that are currently deploying JAK inhibitors in my country and with rapid clinical progress mainly include:

    Hengrui Medicine's JAK1 inhibitor - SHR0302, for rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis


    .


    It can be seen that JAK inhibitors are being developed in full swing in China and around the world, but their potential dangers are gradually being exposed, especially in the past two years, the FDA has warned that JAK inhibitors cause serious heart-related events, cancer, thrombosis and the risk of death.


    Reference: Pharmaceutical Guanlan "JAK Inhibitor in Iteration! A target favored by major companies such as Pfizer, Eli Lilly and Novartis”

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.